Amgen/KK’s Atopic Dermatitis Deal Shows OX40’s Allure, But Market Still Tough

Amgen will pay $400m upfront and up to $850m in milestones

 
• By Alaric DeArment

Amgen said Phase II data are planned for the EADV 2021 meeting, but KHK4083 will need a strong showing.

Dermatitis
Amgen and Kyowa Kirin have signed a deal to develop and commercialize OX40 inhibitor KHK4083 for atopic dermatitis. • Source: Shutterstock

More from Archive

More from Scrip